---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-056254"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T06:18:19.657753+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Amylyx Q1 net loss $118.8M; discontinues RELYVRIO/ALBRIOZA; inventory write-down $110.5M

## Summary
- Net loss of $118.8M ($1.75 diluted per share) vs. net income of $1.6M in Q1 2023.
- Net product revenue $88.6M, up 24% YoY; includes $110.5M non-cash inventory write-down due to product withdrawal.
- Voluntarily discontinuing RELYVRIO/ALBRIOZA for ALS; existing patients transitioned to free drug program.
- Cash $373.3M, expected runway into 2026; interim HELIOS Wolfram data show improvement; topline from 12 patients expected fall 2024.
- Phase 3 ORION PSP trial data expected mid-2025; IND and clinical trial of AMX0114 in ALS planned for H2 2024.

## SEC filing metadata
- accession: 0000950170-24-056254
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000095017024056254/0000950170-24-056254-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000095017024056254/amlx-20240509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-056254
- JSON: https://secwatch.observer/filing/0000950170-24-056254.json
- Plain text: https://secwatch.observer/filing/0000950170-24-056254.txt

## Key facts
- Earnings Releases
  Amylyx Pharmaceuticals, Inc. reported financial results for first quarter ended March 31, 2024.
  - Period: first quarter ended March 31, 2024
  - Result: reported results
  source text: On May 9, 2024, Amylyx Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the fiscal quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1658551/000095017024056254/0000950170-24-056254-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.